Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063162 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
A Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD), sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT05063162 is a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD) that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 104 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05063162, a Phase 3 study of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD), is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rozanolixizumab
Study Locations (20)
Other
- Mog001 30022 - Melbourne
- Mog001 40123 - Anderlecht
- Mog001 40756 - Bruxelles/brussel
- Mog001 40122 - Edegem
- Mog001 40185 - Ghent
- Mog001 60033 - Porto Alegre
Texas
- Mog001 50304 - Dallas
- Mog001 50568 - San Antonio
Arizona
- Mog001 50297 - Scottsdale
California
- Mog001 50450 - Palo Alto
Colorado
- Mog001 50101 - Aurora
District of Columbia
- Mog001 50553 - Washington D.C.
Florida
- Mog001 50308 - Tampa
Illinois
- Mog001 50472 - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05063162
The ClinicalTrials.gov registry entry for NCT05063162 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05063162 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05063162 about?
NCT05063162 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)". The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
What is the current status of trial NCT05063162?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2022-02-02. Estimated completion is 2027-07-01.
What conditions does trial NCT05063162 study?
This clinical trial studies the following conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD).
What interventions are being tested in trial NCT05063162?
The interventions under investigation include: Placebo (OTHER), Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT05063162?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05063162 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.